Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899191 · ClinicalTrials.gov registry record · NA
Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED
A NA study of Type 2 Diabetes and Hyperglycemia, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06899191: Recruiting NA study of Type 2 Diabetes and Hyperglycemia, sponsored by Rutgers, The State University of New Jersey.
NCT06899191 is a NA study of Type 2 Diabetes and Hyperglycemia that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 200 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06899191, a NA study of Type 2 Diabetes and Hyperglycemia, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to improve the processes of Type 2 Diabetes (T2D) care coordination and treatment in the emergency department (ED) by utilizing clinical decision support mechanisms in the electronic health record (EHR). The main question is whether electronic prompts triggered by hyperglycemia and elevated A1c results in providers providing earlier treatments and faster time to subsequent primary care appointment and greater reduction in hemoglobin A1c (HA1c). ED clinicians will receive alerts called Our Practice Advisories (OPA's) through the EPIC EHR. The 1st OPA triggers when a random point-of-care (POC) glucose is ≥250 mg/dL, prompting a suggested additional HA1c order. A 2nd OPA triggers if the resulting HA1c is ≥10%, prompting consideration of further care coordination in the Observation Unit. Investigators will compare the outcomes post-intervention compared to pre-intervention.
Primary Outcome
% Patients achieving: A T2D-related appointment within 4 weeks
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Hemoglobin A1c
- BEHAVIORAL Observation Unit
Study Locations (1)
New Jersey
- Rutgers, Robert Wood Johnson Hospital - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-03-30 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT06899191 shows while recruiting
NCT06899191 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Hemoglobin A1c is the first listed.
NCT06899191 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06899191 about?
NCT06899191 is a clinical study titled "Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED". The goal of this clinical trial is to improve the processes of Type 2 Diabetes (T2D) care coordination and treatment in the emergency department (ED) by utilizing clinical decision support mechanisms in the electronic health record (EHR). The main question is whether electronic prompts triggered by ...
What is the current status of trial NCT06899191?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-03-30. Estimated completion is 2026-03.
What conditions does trial NCT06899191 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Hyperglycemia, Type 2 Diabetes Mellitus (T2DM), Insulin Dependent Diabetes.
What interventions are being tested in trial NCT06899191?
The interventions under investigation include: Hemoglobin A1c (DIAGNOSTIC_TEST), Observation Unit (BEHAVIORAL).
Who is sponsoring clinical trial NCT06899191?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899191 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06899191's enrollment target sits among peer trials
200 99th of 327 higher than 223 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI